The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. Polythiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. Danazol may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The metabolism of Paricalcitol can be increased when combined with Primidone. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. The metabolism of Paricalcitol can be decreased when combined with Clemastine. Indapamide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. Metolazone may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Nevirapine. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The metabolism of Paricalcitol can be increased when combined with Rifampicin. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The metabolism of Paricalcitol can be decreased when combined with Olaparib. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. Quinethazone may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. Paricalcitol may increase the arrhythmogenic activities of Ouabain. The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).